Barnett CL, Denton BT. Optimization of biomarker-based prostate cancer screening policies. In: Sze-chuan Suen, David Scheinker, Eva Enns, editors. Artificial intelligence for healthcare: interdisciplinary partnerships for analytics-driven improvements in a post-COVID world. Cambridge: United Kingdom. Cambridge University Press; 2022. p.141-58.
Johnson M, Gildea (Millar) L. Audit and supervision. In: Daniel Sauca, editors. First do no harm - recommendations for the prevention of healthcare associated infections. Zalău: Romania. Caiete Silvane Publishing House; 2013. p.237-49.
Johnson M, Millar L. Primum non nocere în primul rând sâ nu faci râu; recomandări de prevenire a infecţiilor asociate îngrijirilor medicale. In: Daniel Săuca, editors. Caiete silvane. Zalău: Romania. Carole Hallam & Ramona Marincaş; 2013. p.237-49.
Gilsenan AW, Andrews EB. Considerations and strategies for benefit-risk assessment in the real-world setting. In: Sashegyi A, Felli J, Noel R, editors. Benefit-risk assessment in pharmaceutical research and development. 1st ed. Boca Raton: United States. CRC Press; 2013. p.153-64.
Hawe E, Cockcroft L. The OHE guide to UK health and health care statistics. 2nd ed. London: United Kingdom. OHE Research; 2013.
Rothman KJ. Malattie della bocca. In: Clark DW, MacMahon B, editors. Medicina preventiva e di comunita. Milan: Italy. Liviana Universita Press; 1994.
Rothman KJ. Interpretation of epidemiologic studies on smokeless tobacco and cancer. In: Health implications of smokeless tobacco. Bethesda: MD. NIH Consensus Development Conference; 1986.